MAYO CLINIC LABORATORIES

1-800-533-1710

PVJAK

PV (JAK2 V617F, Exon 12-15) Reflex

Patient ID	Patient Name		Birth Date	Gender	Age
SA00100569	TESTINGRNV, REPORT		1999-11-11	M	17
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00100569	SA00100569	CLIENT, CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		08 Nov 2017 06:00			

PV (JAK2 V617F, Exon 12-15) Reflex

PV Reflex Result

MCR

see interpretation

Specimen Type

MCR

Peripheral blood

Final Diagnosis

[1] MCR

Peripheral blood, JAK2 V617F mutation analysis:

Positive. JAK2 V617F mutated DNA was detected and measured at 69% of total JAK2 DNA.

JAK2V617F mutation is found with high frequency in Philadelphia chromosome-negative myeloproliferative neoplasms (>95% in polycythemia vera and approximately 50–60% in primary myelofibrosis and essential thrombocythemia). It can also occur in other myeloid neoplasms, such as refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) and rarely in myelodysplastic syndrome, chronic myelomonocytic leukemia, atypical chronic myeloid leukemia and acute myeloid leukemia. Clinicopathologic correlation is recommended for a definitive diagnosis.

The precision of JAK2 mutation percentage measurement is such that values 2 times higher or lower than the reported value are considered equivalent.

No further testing for JAK2 mutation was performed as it is not indicated per PVJAK test algorithm. See test catalogue for additional information: http://www.mayocliniclabs.com/test-catalog/Overview/61435.

Method summary - JAK2 V617F analysis: Quantitative, allele-specific polymerase chain reaction (PCR) assay was performed using extracted genomic DNA to evaluate for the point mutation causing JAK2 V617F. The analytic sensitivity of this assay has been determined at 0.06% (see Mayo Medical Laboratories Interpretive Handbook for method details).

Signing Pathologist: Melissa Tricker-Klar

Received: 08 Nov 2017 16:16 **Reported:** 08 Nov 2017 17:27

Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292